ID: ALA2425065

Max Phase: Preclinical

Molecular Formula: C22H26F2N4O

Molecular Weight: 400.47

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC1(C)c2cnc(C3CC3)nc2CN1[C@H]1CO[C@H](c2cc(F)ccc2F)[C@@H](N)C1

Standard InChI:  InChI=1S/C22H26F2N4O/c1-22(2)16-9-26-21(12-3-4-12)27-19(16)10-28(22)14-8-18(25)20(29-11-14)15-7-13(23)5-6-17(15)24/h5-7,9,12,14,18,20H,3-4,8,10-11,25H2,1-2H3/t14-,18+,20-/m1/s1

Standard InChI Key:  UBOJLBRUXZIMSC-HEFCMCLBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 400.47

Molecular Weight (Monoisotopic): 400.2075

AlogP: 3.54

#Rotatable Bonds: 3

Polar Surface Area: 64.27

Molecular Species: BASE

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.82

CX LogP: 2.87

CX LogD: 1.44

Aromatic Rings: 2

Heavy Atoms: 29

QED Weighted: 0.85

Np Likeness Score: -0.47

References

1. Biftu T, Qian X, Chen P, Feng D, Scapin G, Gao YD, Cox J, Roy RS, Eiermann G, He H, Lyons K, Salituro G, Patel S, Petrov A, Xu F, Xu SS, Zhang B, Caldwell C, Wu JK, Lyons K, Weber AE..  (2013)  Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2- (2,5-difluorophenyl)-5-(4,6-dihydropyrrolo [3,4-c]pyrazol-5-(1H)-yl)tetrahydro-2H-pyran-3-amine (23) [corrected].,  23  (19): [PMID:23972441] [10.1016/j.bmcl.2013.07.061]

Source

Source(1):

• Scientific Literature